​

Cartesian Therapeutics (RNAC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RNAC Stock Forecast

Cartesian Therapeutics (RNAC) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $42.67, with a high of $45.00 and a low of $40.00. This represents a 541.65% increase from the last price of $6.65.

- $9 $18 $27 $36 $45 High: $45 Avg: $42.67 Low: $40 Last Closed Price: $6.65

RNAC Stock Rating

Cartesian Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (75.00%), 2 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 6 Strong Sell Sell Hold Buy Strong Buy

RNAC Price Target Upside V Benchmarks

TypeNameUpside
StockCartesian Therapeutics541.65%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.65$6.65$6.65
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-62--8
Nov, 25252--9
Oct, 25252--9
Sep, 25252--9
Aug, 25252--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 09, 2024Mitchell KapoorH.C. Wainwright$45.00$12.87249.65%576.69%
Jul 03, 2024John NewmanCanaccord Genuity$43.00$15.77172.67%546.62%
May 24, 2024Uy EarMizuho Securities$40.00$25.4657.11%501.50%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2024BTIGBuyinitialise
Sep 04, 2024H.C. WainwrightBuyBuyhold
Aug 09, 2024H.C. WainwrightBuyBuyhold
Aug 06, 2024Cowen & Co.Buyinitialise
Jul 02, 2024OppenheimerOutperformPerformdowngrade
Jun 14, 2024OppenheimerOutperformOutperformhold
Jun 04, 2024OppenheimerOutperforminitialise

Financial Forecast

EPS Forecast

$-45 $-34 $-23 $-12 $-1 $10 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-20.42$-6.74$7.33$-42.49$-0.50----
Avg Forecast$-19.07$-10.59$1.49$-5.25$-5.99$-3.47$-3.69$-5.05$-4.75
High Forecast$-17.03$-9.46$1.51$-0.58$-5.75$-1.88$-1.61$-3.18$-4.75
Low Forecast$-22.69$-12.60$1.48$-9.63$-6.22$-4.55$-5.23$-6.24$-4.75
Surprise %7.08%-36.36%391.95%709.33%-91.65%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$16.60M$85.08M$110.78M$26.00M$38.91M----
Avg Forecast$10.81M$68.16M$96.20M$10.60M$39.74M$6.29M$8.80M$5.00M$34.30M
High Forecast$12.39M$78.11M$96.85M$13.74M$40.06M$6.29M$8.80M$5.00M$34.30M
Low Forecast$9.92M$62.56M$95.53M$7.46M$39.56M$6.29M$8.80M$5.00M$34.30M
Surprise %53.56%24.83%15.15%145.32%-2.08%----

Net Income Forecast

$-250M $-190M $-130M $-70M $-10M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-68.88M$-25.69M$35.38M$-219.71M$-77.42M----
Avg Forecast$-98.41M$-54.63M$7.72M$-26.39M$-30.95M$-16.61M$-17.68M$-24.35M$-24.57M
High Forecast$-87.90M$-48.79M$7.78M$-3.02M$-29.75M$-9.70M$-8.32M$-16.44M$-24.57M
Low Forecast$-117.10M$-65.00M$7.65M$-49.76M$-32.15M$-23.51M$-27.04M$-32.26M$-24.57M
Surprise %-30.01%-52.98%358.46%732.55%150.15%----

RNAC Forecast FAQ

Is Cartesian Therapeutics stock a buy?

Cartesian Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cartesian Therapeutics is a favorable investment for most analysts.

What is Cartesian Therapeutics's price target?

Cartesian Therapeutics's price target, set by 8 Wall Street analysts, averages $42.67 over the next 12 months. The price target range spans from $40 at the low end to $45 at the high end, suggesting a potential 541.65% change from the previous closing price of $6.65.

How does Cartesian Therapeutics stock forecast compare to its benchmarks?

Cartesian Therapeutics's stock forecast shows a 541.65% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Cartesian Therapeutics over the past three months?

  • December 2025: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 22.22% Strong Buy, 55.56% Buy, 22.22% Hold, 0% Sell, 0% Strong Sell.

What is Cartesian Therapeutics’s EPS forecast?

Cartesian Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.47, marking a 594.00% increase from the reported $-0.5 in 2024. Estimates for the following years are $-3.69 in 2026, $-5.05 in 2027, and $-4.75 in 2028.

What is Cartesian Therapeutics’s revenue forecast?

Cartesian Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $6.29M, reflecting a -83.85% decrease from the reported $38.91M in 2024. The forecast for 2026 is $8.8M, followed by $5M for 2027, and $34.3M for 2028.

What is Cartesian Therapeutics’s net income forecast?

Cartesian Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-16.606M, representing a -78.55% decrease from the reported $-77.424M in 2024. Projections indicate $-17.682M in 2026, $-24.352M in 2027, and $-24.572M in 2028.